CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	OBERMANNOVÁ Radka SELINGEROVÁ Iveta DEMLOVÁ Regina VALÍK Dalibor ZDRAŽILOVÁ DUBSKÁ Lenka KISS Igor
Year of publication	2023
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.
Related projects:	CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network